Compare WETH & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | APVO |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1M | 21.7M |
| IPO Year | N/A | N/A |
| Metric | WETH | APVO |
|---|---|---|
| Price | $1.68 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.6K | ★ 1.1M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.55 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $43,519,385.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.76 | $1.04 |
| 52 Week High | $3.68 | $298.00 |
| Indicator | WETH | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 33.26 |
| Support Level | $1.75 | $1.07 |
| Resistance Level | $2.04 | $1.41 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 4.26 | 13.28 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.